scholarly journals Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer

2021 ◽  
Vol 10 (3) ◽  
pp. 1034-1042
Author(s):  
Mikko Loukovaara ◽  
Annukka Pasanen ◽  
Ralf Bützow
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Therapy ◽  
Mismatch Repair ◽  
Methylation Status ◽  
Predictors Of Response ◽  
Repair Protein ◽  
Mlh1 Methylation ◽  
Mismatch Repair Protein

Mismatch repair protein status and effect on outcomes in high-intermediate risk endometrial cancer

2020 ◽  
Vol 159 ◽  
pp. 210-211
Author(s):  
A.M. Barrie ◽  
M.T. McHale ◽  
C.C. Saenz ◽  
S.C. Plaxe ◽  
R.N. Eskander
Keyword(s):  
Endometrial Cancer ◽  
Mismatch Repair ◽  
Intermediate Risk ◽  
Protein Status ◽  
Repair Protein ◽  
Mismatch Repair Protein

DNA mismatch repair protein defects and endometrial cancer in women age 40 and younger

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5579-5579
Author(s):  
K. K. Shih ◽  
K. Garg ◽  
D. A. Levine ◽  
N. Kauff ◽  
N. R. Abu-Rustum ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Mismatch Repair ◽  
Young Women ◽  
Dna Mismatch Repair ◽  
High Grade ◽  
Advanced Stage ◽  
Dna Mismatch ◽  
Repair Protein ◽  
Mismatch Repair Protein

5579 Background: The significance of the hereditary basis of endometrial cancer is apparent in young women with endometrial cancer. The objective of this study was to describe the incidence and prognostic implications of DNA mismatch repair protein defects in a series of patients age 40 years and younger with endometrial cancer. Methods: We performed a retrospective cohort study of patients age 40 years or less who were diagnosed with endometrial carcinoma between 1/93 and 5/08. Clinical and pathologic data were extracted from medical records. Paraffin-embedded slides from hysterectomy specimens were obtained and DNA mismatch repair (MMR) immunohistochemistry (IHC) was performed. Cases were analyzed according to presence of DNA MMR protein defects. Standard two-sided statistical tests were performed. Results: Of the 71 identified patients, the median age was 37 years (range, 24–40), with a median follow-up of 47 months (range, 1–178). The majority were of endometrioid histology (94%), stage I (73%), and FIGO grade 1 (61%). IHC was performed with available blocks (n = 56), and loss of DNA MMR was found in 9 cases (16%). Cases with loss of DNA MMR were more likely to have high-grade (FIGO 2 or 3) tumors (p < 0.001), be advanced stage (III or IV) at the time of diagnosis (p < 0.001), and have a family history suggestive of hereditary non-polyposis colorectal cancer (p = 0.01). There was no difference between the groups in histology, obesity (BMI>30), parity, or history of infertility. Analysis of clinical outcomes revealed that cases with loss of DNA MMR had significantly worse overall survival (median survival not reached, log rank p = 0.018). At the time of last follow-up, 2 (22%) patients with loss of DNA MMR were dead of disease compared with 2 (4%) patients with retained DNA MMR. Conclusions: Endometrial cancer is rare in young women age 40 years or less. In these patients, loss of DNA MMR was associated with worse clinicopathologic factors (high-grade and advanced-stage tumors) and worse outcome. Other clinical risk factors associated with endometrial cancer were not associated with loss of DNA MMR. The data suggest that MMR testing in women 40 years of age or younger with endometrial cancer may have clinically useful prognostic information. No significant financial relationships to disclose.

Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer

2009 ◽  
Vol 114 (3) ◽  
pp. 486-490 ◽  
Author(s):  
Floor J. Backes ◽  
Marino E. Leon ◽  
Iouri Ivanov ◽  
Adrian Suarez ◽  
Wendy L. Frankel ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Protein Expression ◽  
Mismatch Repair ◽  
Dna Mismatch Repair ◽  
Prospective Evaluation ◽  
Dna Mismatch ◽  
Repair Protein ◽  
Mismatch Repair Protein

Effect of mismatch repair protein status on outcomes in high intermediate risk endometrial cancer

2021 ◽  
Vol 162 ◽  
pp. S144-S145
Author(s):  
Marianne Hom ◽  
Erin Mowers ◽  
Allison Barrie ◽  
Terry Harrison ◽  
Jessica Jou ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Mismatch Repair ◽  
Intermediate Risk ◽  
Protein Status ◽  
Repair Protein ◽  
Mismatch Repair Protein
Sign in / Sign up

Export Citation Format

Share Document